Přístupnostní navigace
E-přihláška
Vyhledávání Vyhledat Zavřít
Detail publikace
HADDAD, Y. REMEŠ, M. ADAM, V. HEGER, Z.
Originální název
Toward structure-based drug design against the epidermal growth factor receptor (EGFR)
Typ
článek v časopise ve Web of Science, Jimp
Jazyk
angličtina
Originální abstrakt
Most of the available crystal structures of epidermal growth factor receptor (EGFR) kinase domain, bound to drug inhibitors, originated from ligand-based drug design studies. Here, we used variations in 110 crystal structures to assemble eight distinct families highlighting the C-helix orientation in the N-lobe of the EGFR kinase domain. The families shared similar mutational profiles and similarity in the ligand R-groups (chemical composition, geometry, and charge) facing the C-helix, mutation sites, and DFG domain. For structure-based drug design, we recommend a systematic decision-making process for choice of template, guided by appropriate pairwise fitting and clustering before the molecular docking step. Alternatively, the binding site shape/volume can be used to filter and select the compound libraries.
Klíčová slova
Structure-Based Drug Design; epidermal growth factor receptor (EGFR); kinase domain; molecular docking
Autoři
HADDAD, Y.; REMEŠ, M.; ADAM, V.; HEGER, Z.
Vydáno
28. 2. 2021
ISSN
1359-6446
Periodikum
DRUG DISCOVERY TODAY
Ročník
26
Číslo
2
Stát
Spojené království Velké Británie a Severního Irska
Strany od
289
Strany do
295
Strany počet
7
URL
https://www.sciencedirect.com/science/article/pii/S1359644620304220
BibTex
@article{BUT170589, author="Yazan Abdulmajeed Eyadh {Haddad} and Marek {Remeš} and Vojtěch {Adam} and Zbyněk {Heger}", title="Toward structure-based drug design against the epidermal growth factor receptor (EGFR)", journal="DRUG DISCOVERY TODAY", year="2021", volume="26", number="2", pages="289--295", doi="10.1016/j.drudis.2020.10.007", issn="1359-6446", url="https://www.sciencedirect.com/science/article/pii/S1359644620304220" }